Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 12, 2005 12:50 ET | Source: ViroPharma Incorporated

ViroPharma Incorporated Announces Completion of Offering

EXTON, Pa., Dec. 12, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced the completion of its previously announced underwritten public offering of 10,350,000 shares of newly...
December 09, 2005 07:32 ET | Source: ViroPharma Incorporated

ViroPharma Incorporated Announces Exercise of Option to Purchase Additional Securities

EXTON, Pa., Dec. 9, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that the underwriters of its recent public offering of 9,000,000 shares of common stock have exercised in...
December 08, 2005 15:35 ET | Source: ViroPharma Incorporated

Recent Key Publications Describe Evolving Epidemic of Severe Clostridium difficile-Associated Disease

EXTON, Pa., Dec. 8, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that The New England Journal of Medicine (NEJM) and the Center for Disease Control and Prevention's (CDC)...
December 07, 2005 06:35 ET | Source: ViroPharma Incorporated

ViroPharma Incorporated Prices Public Offering of Common Stock

EXTON, Pa., Dec. 7, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced the pricing of an underwritten public offering of 9,000,000 shares of newly issued common stock at $16.75...
November 28, 2005 16:01 ET | Source: ViroPharma Incorporated

ViroPharma Incorporated Announces Public Offering of Common Stock

EXTON, Pa., Nov. 28, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that it plans to offer 7,000,000 shares of its common stock in a public offering. ViroPharma also...
November 28, 2005 11:06 ET | Source: ViroPharma Incorporated

ViroPharma Completes Enrollment in Phase 2 Clinical Study of Maribavir in Bone Marrow Transplant Patients

EXTON, Pa., Nov. 28, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that it has completed enrollment in its Phase 2 clinical study for maribavir, an oral antiviral drug...
November 22, 2005 15:13 ET | Source: ViroPharma Incorporated

ViroPharma to Present at the Lazard Capital Markets Life Sciences Conference

EXTON, Pa., Nov. 22, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that it will present at the Lazard Capital Markets Life Sciences Conference, at 1:30 P.M. EST on...
November 14, 2005 09:18 ET | Source: ViroPharma Incorporated

ViroPharma Selected for NASDAQ Biotechnology Index

EXTON, Pa., Nov. 14, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that it has been selected to become a member of the NASDAQ Biotechnology Index(R). ViroPharma's...
November 11, 2005 14:23 ET | Source: ViroPharma Incorporated

ViroPharma to Present at the 2005 Credit Suisse First Boston Health Care Conference

EXTON, Pa., Nov. 11, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that it will present at the 2005 Credit Suisse First Boston Health Care Conference, at 3:30 p.m. MST...
November 10, 2005 12:47 ET | Source: ViroPharma Incorporated

ViroPharma to Host Conference Call to Discuss Clinical Results of HCV-796

EXTON, Pa., Nov. 10, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that the company will host a conference call and live audio webcast today at 4:30 p.m. to discuss the...